Exclusive worldwide license agreement signed with the University of California at San Diego for two new, novel oxime drug technologies. June 18, 2014 • admin • General News, Pharmaceuticals Read More »
Countervail Corporation Receives Additional $5.4 Million from BARDA For Continued Development of Medical Countermeasure to Nerve Agents October 25, 2013 • admin • Funding, General News, Pharmaceuticals Read More »
Pre-IND FDA Meeting held to obtain guidance on development of galantamine as a pre-treatment for nerve agent exposure. March 17, 2009 • admin • General News, Pharmaceuticals Read More »
Countervail Corporation has been awarded $25,000 in matching business development funding from the NC BioTech Center in support of FDA Pre-IND activities for product commercialization. June 4, 2008 • admin • Funding, Pharmaceuticals Read More »
Master License Agreement Signed with University of Maryland Baltimore for the use of galantamine as a treatment for organophosphate poisoning July 12, 2007 • admin • Military, Pharmaceuticals Read More »